MIRM - NASDAQ
Mirum Pharmaceuticals, Inc.
$91.83
-0.016%Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Mirum Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Foster City, California.
At a Glance
Live SnapshotMirum Pharmaceuticals, Inc. Fair Value Envelope
Owner Earnings Valuation Tool
Warren Buffett's Owner Earnings DCF analysis for intrinsic value calculation
Historical Financial Data
Base year metrics used for projections
Projection Settings
Forecast period and terminal assumptions
DCF Valuation Summary
Calculation flow from present value to intrinsic value per share
Owner Earnings Projections
Operating Cash Flow - Maintenance CapEx = Owner Earnings
| Metric | Year 1 | Year 2 | Year 3 | Year 4 | Year 5 | Year 6 | Year 7 | Year 8 | Year 9 | Year 10 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $111.7M | $223.3M | $446.6M | $893.2M | $1.8B | $3.6B | $7.1B | $14.3B | $28.6B | $57.2B |
| Maintenance CapEx | -$381.6K | -$763.2K | -$1.5M | -$3.1M | -$6.1M | -$12.2M | -$24.4M | -$48.8M | -$97.7M | -$195.4M |
| Owner Earnings | $111.3M | $222.5M | $445.1M | $890.2M | $1.8B | $3.6B | $7.1B | $14.2B | $28.5B | $57.0B |
| Discount Factor | 0.926 | 0.857 | 0.794 | 0.735 | 0.681 | 0.630 | 0.583 | 0.540 | 0.500 | 0.463 |
| Present Value | $103.0M | $190.8M | $353.3M | $654.3M | $1.2B | $2.2B | $4.2B | $7.7B | $14.2B | $26.4B |
Related Guides
Continue your MIRM research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.